Rezika Mohammed
Overview
Explore the profile of Rezika Mohammed including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
575
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Griensven J, van Henten S, Kibret A, Kassa M, Beyene H, Abdellati S, et al.
EBioMedicine
. 2024 Nov;
110:105474.
PMID: 39612653
Background: Targeted preventive strategies in persons living with HIV (PLWH) require markers to predict visceral leishmaniasis (VL). We conducted a longitudinal study in a HIV-cohort in VL-endemic North-West Ethiopia to...
2.
de Vrij N, Vandoren R, Ramadan K, Van Hul A, Ceulemans A, Kassa M, et al.
PLoS Negl Trop Dis
. 2024 Sep;
18(9):e0012000.
PMID: 39348450
Human immunodeficiency virus (HIV) co-infection is a major challenge for visceral leishmaniasis (VL) control, particularly in Ethiopia where the incidence of both pathogens is high. VL-HIV often leads to high...
3.
Chu W, Verrest L, Younis B, Musa A, Mbui J, Mohammed R, et al.
J Infect Dis
. 2024 Aug;
230(6):e1375-e1384.
PMID: 39166299
Treatment regimens for post-kala-azar dermal leishmaniasis (PKDL) are usually extrapolated from those for visceral leishmaniasis (VL), but drug pharmacokinetics (PK) can differ due to disease-specific variations in absorption, distribution, and...
4.
de Vrij N, Pollmann J, Rezende A, Ibarra-Meneses A, Pham T, Hailemichael W, et al.
Commun Biol
. 2024 May;
7(1):524.
PMID: 38702419
A large proportion of HIV-coinfected visceral leishmaniasis (VL-HIV) patients exhibit chronic disease with frequent VL recurrence. However, knowledge on immunological determinants underlying the disease course is scarce. We longitudinally profiled...
5.
Messele Kebede A, Sutanto E, Trimarsanto H, Diez Benavente E, Barnes M, Pearson R, et al.
Sci Rep
. 2023 Nov;
13(1):20788.
PMID: 38012191
Ethiopia has the greatest burden of Plasmodium vivax in Africa, but little is known about the epidemiological landscape of parasites across the country. We analysed the genomic diversity of 137...
6.
Verrest L, Roseboom I, Wasunna M, Mbui J, Njenga S, Musa A, et al.
J Antimicrob Chemother
. 2023 Sep;
78(11):2702-2714.
PMID: 37726401
Objectives: To improve visceral leishmaniasis (VL) treatment in Eastern Africa, 14- and 28-day combination regimens of paromomycin plus allometrically dosed miltefosine were evaluated. As the majority of patients affected by...
7.
Fikre H, Teklehaimanot E, Mohammed R, Mengistu M, Abebe B, van Griensven J, et al.
Case Rep Infect Dis
. 2023 Apr;
2023:2768626.
PMID: 37096133
Cutaneous leishmaniasis is a neglected tropical disease affecting mostly the exposed skin, causing severe and disfiguring lesions in Ethiopia. In this report, we present two cases of atypical mucocutaneous leishmaniasis;...
8.
Mohammed R, Melkamu R, Pareyn M, Abdellati S, Bogale T, Engidaw A, et al.
PLoS Negl Trop Dis
. 2023 Mar;
17(3):e0011142.
PMID: 36893183
Visceral leishmaniasis (VL) is a disease caused by Leishmania parasites. While predominantly transmitted by sandflies, cases of VL transmitted through blood transfusion have been reported, particularly in immunocompromised recipients. Although...
9.
Melkamu R, Berhane N, Jacobs B, Mohammed R, Kassa M, Yeshanew A, et al.
PLoS Negl Trop Dis
. 2023 Feb;
17(2):e0011128.
PMID: 36780561
Background: As untreated visceral leishmaniasis (VL) is fatal, reliable diagnostics are pivotal for accurate treatment allocation. The current diagnostic algorithm for VL in Ethiopia, which is based on the rK39...
10.
Kassaw G, Mohammed R, Tessema G, Yesuf T, Lakew A, Tarekegn G
Infect Drug Resist
. 2023 Feb;
16:619-635.
PMID: 36743334
Background: Severe community-acquired pneumonia is a common life-threatening infection with a high rate of unfavorable outcome. This study aimed to assess the outcomes and predictors of hospitalized severe community-acquired pneumonia...